budesonide (MAP0010) / AbbVie  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
budesonide (MAP0010) / AbbVie
NCT00697801: Study of MAP0010 in Asthmatic Children and Adolescents

Completed
2
208
US
MAP0010 low dose, MAP0010 high dose, Placebo
Allergan, MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan
Asthma
12/06
12/06
P202, NCT00554970: A Study of 2 Doses of MAP0010 in Adult Asthmatics

Completed
2
32
US
MAP0010 low dose, MAP0010 high dose, Budesonide inhalation suspension 0.25mg, Pulmicort Respules®, Budesonide inhalation suspension 0.5mg
Allergan, MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan
Asthma
01/08
03/08
NCT00995904: Tolerability and PK of Submicron Budesonide in Children 4 to 11 Years Old With Mild-To-Moderate Stable Asthma

Completed
2
25
US
84ug MAP0020, 42ug MAP0020, 21ug MAP0020
Allergan, MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan
Asthma
11/09
11/09

Download Options